Cancer drug shows promise for Alzheimer's in tiny study
NCT ID NCT04070378
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This small pilot study tested daratumumab, a cancer drug, in 16 people with mild to moderate Alzheimer's. The goal was to see if it could improve thinking and memory. Participants received daratumumab injections under the skin. The study was open-label, meaning everyone knew they were getting the drug, and there was no placebo group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- daratumumab
- What this could lead to
- If this works, daratumumab could offer a new way to slow or improve cognitive decline in Alzheimer's disease.
- What could go wrong
- This is a very small, early pilot study with only 16 people and no placebo group. Results may not be reliable or apply to larger populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Litwin-Zucker Research Center
Manhasset, New York, 11030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple questionnaire empower dementia caregivers after hospital stays?
- Could your heart hold the key to Alzheimer's prevention?
- Can a nudge in your chart unlock Life-Saving genetic clues?
- Can a Voice-Based app map healthy brain aging across 80 years?
- Can MRI reveal the Brain's response to deep brain stimulation?
- Can brain scans and gut bacteria reveal Alzheimer's secrets?